NCT05155306View on ClinicalTrials.gov

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
Healthy
Interventions
DRUG

BI 1358894, intended Commercial Formulation (iCF) (T)

A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning

DRUG

BI 1358894, Trial Formulation 2 (TFII) (R)

A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning.

Trial Locations (1)

88397

Humanpharmakologisches Zentrum Biberach, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05155306 - A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food | Biotech Hunter | Biotech Hunter